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Available online 9 April 2016The human embryonic stem cell line RCe020-A (RC-16) was derived under quality assured compliance with UK
regulation, EuropeanUnionDirectives and International guidance for tissue procurement, processing and storage
according to GoodManufacturing Practice (GMP) standards. The cell linewas derived froma failed to fertilise oo-
cyte voluntarily donated as unsuitable or surplus to fertility requirements following informed consent. RCe020-A
(RC-16) shows normal pluripotency marker expression and differentiates to mesoderm and potentially ecto-
derm in vitro. It has an abnormal 47XX, +14, i(20)(q10) female karyotype and microsatellite PCR identity,
HLA and blood group typing data is available.
© 2016 Roslin Cells Ltd. Published by Elsevier B.V. This is an open access article under the CC BY license
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RCe020-A (RC-16) was received as a failed to fertilise oocyte/1PN
(pro-nuclear) embryo that was surplus to requirement or unsuitable
for clinical use andwas cultivated to blastocyst stage. Human embryonic
stem cell (hESC) isolation, expansion and qualiﬁcation was performed
in a facilities whose speciﬁcation, operation and monitoring complied
with GMP standards enabling; i) a fully traceable procurement procedure
with informed ethical consent which includes provision for commercial
use, ii) detailed medical history and blood borne virus (BBV) screening
of donors, and iii) compilation of a cell line history providing details on
hESC manufacturing process and quality control testing regime.
Human ESC culture and processing was performed in a grade A
tissue culture cabinet in a grade B clean room environment monitored
for particulate and microbiological contamination during cell
processing in accordance with Rules and Guidance for Pharmaceuti-
cal anufacturers and Distributors — The Orange Guide, compiled by
the UK Medicines Healthcare Products Regulatory Authority (Go to:
https://www.gov.uk/guidance/good-manufacturing-practice-and-
good-distribution-practice). Accordingly, the facility was operating
under a mature Quality Management System, compliant with
ISO9001:2008 standards. HESC derivation was performed under
licensure from the UK HFEA (R0136 to centre 0202) and HTA
(Licensing Number 22631).
Derivation of hESCs involved whole embryo outgrowth on
mitotically inactivated human dermal ﬁbroblast (HDF) feeder cells.
HDFs were derived and manufactured according to GMP and had been
approved for clinical use by the Food and Drug Administration, USA.der the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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therapy grade media (XF KODMEM) supplemented with xeno-free
human recombinant bFGF. HESCs were subsequently expanded in a
GMP grade serum-free medium (StemPro hESC Serum Free Medium)
on a xeno-free matrix (CellStart). The former contained bovine serum
albumin (BSA) from a Transmissible Spongioform Encephalopathy
(TSE)-free country of origin. The cell line was cryopreserved in a GMP
compliant cryopreservation solution (CryoStor CS10).
By ﬂow cytometry, RCe020-A (RC-16) expressed the pluripotency
makers Oct-4, Tra-1-60 and SSEA-4 (85.7%, 85.8% and 94.6%, respective-
ly), whereas low expression of the differentiationmarker SSEA-1 (0.0%)
was observed (Figs. 1, 2). To assess the differentiation potential of the
cell line, embryoid body formation in vitro was used and showed
differentiation to the mesoderm lineage by expression of muscle actin.
RCe020-A (RC-16) may also be able to differentiate to ectoderm, as
atypical staining with an antibody to β-tubulin was also observed, but
at the seed banking stage there was no expression of α-fetoprotein
(endoderm) (Fig. 3).Fig. 1. Quality Control Certiﬁcate of AnalysiA microsatellite PCR proﬁle has been obtained for the cell line, and
HLA Class I and II typing is available (Table 1). Blood group genotyping
gave the blood group AO1 (Table 1).
3. Veriﬁcation and authentication
The cell line was analysed for genome stability by G-banding and
showed a female genotype with extra copy of chromosome 14, in
addition to an isochromosome for the long arm of chromosome 20
(47XX, +14, i(20)(q10)) in all 30 cells examined (Fig. 4). The cell line
is free from mycoplasma contamination as determined by RT-qPCR.
4. Materials and methods
4.1. Ethics
Derivation of hESC from surplus to requirement and failed to
fertilise/develop embryos was approved by The Scotland As for RCe020-A (RC-16) P18A seed lot.
Fig. 1 (continued).
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ing fertility clinics and conducted under licence no R0136 from
the UK HFEA with informed donor consent. The processing andFig. 2. RCe020-A (RC-16) was subjected to ﬂow cytometry analysis for markers of pluripotency
histograms. Percentage staining is indicated in the Certiﬁcate of Analysis (Fig. 1).storage of hESC cells for human application was conducted
under licence number 22631 from the UK Human Tissue
Authority.with speciﬁc antibody (top row) or isotype control (bottom row) as indicated above the
Fig. 3. In vitro differentiation of RCe020-A (RC-16) to mesoderm (muscle Actin), but not endoderm (α-fetoprotein). Atypical staining was observed for ectoderm (β-tubulin III). Speciﬁc
staining shown in green, cell nuclei are counterstained with DAPI (blue).
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Fresh embryos were cultured in Sydney cleavage medium (Cook
Medical, Hertfordshire, UK) until day 3 and Sydney blastocyst medium
(Cook Medical) after day 3 of development. Embryos were cultured at
36.5–37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 in drops under parafﬁn oil
(CookMedical) and transferred to freshmedium at least every 2–3 days.
By day 8 of development, embryos were placed in derivation condi-
tions consisting of mitotically inactivated GMP grade neonatal human
dermal ﬁbroblasts (HDFs) (Forticell Biosciences, NJ, USA) on tissue
culture plastic in XF KODMEMmedium (Knockout-DMEM, 15% KOSR-
XF, 2 mM L-glutamine, 1% MEM Non essential amino acids, 2% XF
Growth Factor Cocktail, 0.1 mM β-mercaptoethanol (ThermoFisher
Scientiﬁc, Paisley, UK) supplemented with 80 ng/ml human bFGF
(ThermoFisher Scientiﬁc). When available, cell therapy system quality
reagents were used. Assisted hatching was performed by removing
the zona pellucidaemechanically using Swemed cutting tools (Vitrolife,
Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% Pharma
grade FCS (GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-
glutamine (ThermoFisher Scientiﬁc). HDF were mitotically inactivated
using gamma irradiation at 50 Gy using a Gammacell Elite 1000
machine. For use as a feeder layer, irradiated HDFs were plated at
50,000 cells/cm2 in XF KODMEM medium supplemented with
80 ng/ml human bFGF (ThermoFisher Scientiﬁc). Cells were cultured
at 36.5–37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 and 50% medium
exchanged 6 days a week.
The established cell line was expanded and banked using CellStart
matrix and Stempro hESC Serum Free Medium (cell therapy system
quality reagents, ThermoFisher Scientiﬁc). This contained BSA from a
TSE-free country of origin. Passaging was performed mechanicallyTable 1
Microsatellite PCR, blood group and HLA tissue typing results for RCe020-A (RC-16).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2
17 18 17 19
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2
X X 11 13
D19S433 1 D19S433 2 THO1 1 THO1 2
14 14 6 9.3
D5S818 1 D5S818 2 D7S820 1 D7S820 2
11 11 10 11
Blood group genotyping
RhD RhC Rhc RhE
Neg Neg Pos Neg
Jka Jkb K k
Pos Pos Neg Pos
Do a Do b ABO
neg pos AO1
HLA tissue typing
HLA Class I Type HLA-A*02, A*24; B*07, B*57; C*06, C*07
HLA Class II Type HLA-DRB1*13, DRB1*15; DRB3*01; DRB5*01; DQB1*03, DQB1
Comment DQB1*03 is expressed serologically as DQ7using an EZ passage tool (ThermoFisher Scientiﬁc). hESC lines were
expanded to 25–30 wells of a 6-well plate and cryopreserved in 0.5–
1 ml Cryostor CS10 (Biolife Solution, Washington, USA) using an
EF600–107 controlled rate freezer (Grant Instruments, Cambridge,
UK) before being stored in a−150 °C freezer (Panasonic Biomedical,
Loughborough, UK).
4.3. Mycoplasma
In process mycoplasma detection was performed using Applied
Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and
MicroSEQ™Mycoplasma Real-Time PCR Detection Kit (ThermoFisher
Scientiﬁc (Applied Biosystems)) according to the manufacturer's
instruction.
4.4. Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according to
the manufacturer's instructions. Brieﬂy, an unknown sample was
compared with a standard curve of known levels of control endotoxin.
An assay was deemed valid if the coefﬁcient of correlation, r ≥ 0.980
and the CV (%) for the standard curve was ≤10%, and the reaction time
of the negative control was greater than the reaction time of the lowest
standard on the standard curve.
4.5. Flow cytometry
Pluripotency was determined using the Human andMouse Pluripo-
tent Stem Cell Analysis kit (BD, Oxford, UK). Oct. 3/4 and SSEA-4 were
included as pluripotency markers, and SSEA-1 as a differentiationD16S539 1 D16S539 2 D2S1338 1 D2S1338 2
11 11 18 25
D21S11 1 D21S11 2 D18S51 1 D18S51 2
29 30 12 16
FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
20 23 11 13
D13S317 1 D13S317 2 TPOX 1 TPOX 2
11 12 11 12
Rhe Fy a Fy b Fy GATA
pOs Neg Pos Neg
M N S s
Neg Pos Neg Pos
*06
Fig. 4. RCe020-A (RC-16) was analysed by Giesma staining of 30 metaphase spreads at passage 22 and showed a female genotype with extra copy of chromosome 14, in addition to an
isochromosome for the long arm of chromosome 20 (47XX, +14, i(20)(q10)).
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pluripotency marker. Fixed and permeabilized cells were analysed
using a FACS Aria ﬂow cytometer (BD) or a Guava easyCyte ﬂow
cytometer (Millipore, Watford, UK). Percentage expression of each
marker was compared to isotype control or unstained cells.
4.6. Viability
Viability was determined using the Guava ViaCount assay. Brieﬂy,
the Guava Viacount reagent (Millipore) containing a nuclear and a
viability dye, was mixed with a single cell suspension, incubated for
5 min and analysed using the Guava easyCyte ﬂow cytometer
(Millipore). Total cell count, viable cell count and percentage viable
cells was obtained.
4.7. In vitro differentiation
hESCs were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) and embryoid bodies
(EBs) generated in ultra low attachment plates (Corning) for 7 days be-
fore being transferred into EBmedium (20% FBS (GE Healthcare (PAA)),
80% KO-DMEM 1mM L-glutamine, 3.5 μM β-mercaptoethanol, 1% non-
essential amino acids (all ThermoFisher Scientiﬁc)), on glass slide tissue
culture chambers (Nunc, ThermoFisher Scientiﬁc) coated with 0.2%
gelatin (Sigma Aldrich, Dorset, UK) at 0.1 ml/cm2 for 14 days.
4.8. Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde (ThermoFisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher
Scientiﬁc) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000;
Sigma) and muscle-speciﬁc actin (1:50; DAKO, Glostrup, Denmark)
and secondary antibody anti mouse IgG-AlexaFluor 488 (1:200;Sigma). Images were acquired using a Zeiss S100 Axiovert ﬂuorescence
microscope or Nikon eC1 confocal microscope.
4.9. Genomic analysis and outsourced assays
All outsourced assayswere carried out under aQuality and Technical
Agreement. DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Manchester, UK) according to manufacturer's recommenda-
tions and provided in recommended quantities to the service
providers.
Microsatellite PCR, or Short Tandem Repeat analysis, was used to
determine cell line identity and was carried out by Public Health En-
gland. A proﬁle was obtained for the following core alleles: vWA,
D16S539, Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and
TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular Diagnos-
tics laboratory at NHSBT.
Karyotype analysis was carried out by the Western General Cytoge-
netics Laboratory (Edinburgh, UK). Live cells at 60–70% conﬂuencywere
shipped in warm containers, ﬁxed and analysed by standard G-banding
analysis. For clinical grade lines, 30 spreads were analysed.
Viral screening for cytomegalovirus (CMV), Human T-cell
lymphotropic virus (HTLV)-1, Human immunodeﬁciency virus (HIV)-
1, Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Epstein–Barr
virus (EBV) was carried out by The Doctors Laboratory (London, UK).
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